PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF REPLACING PCV13 WITH PCV15 IN THE NATIONAL IMMUNIZATION PROGRAM IN SAUDI ARABIA

被引：0
|
作者：
Huang, M. [1 ]
Weaver, J. [2 ]
Albassam, G. [3 ]
Akel, R. [4 ]
Chhabra, N. [5 ]
Ranjan, S. [5 ]
Gupta, S. [6 ]
Ugrekhelidze, D. [7 ]
机构：
[1] Merck & Co Inc, Merck Res Labs, Rahway, NJ USA
[2] Merck & Co Inc, Rahway, NJ USA
[3] MSD, Riyadh, Saudi Arabia
[4] MSD, Dubai, U Arab Emirates
[5] CHEORS, North Wales, PA USA
[6] CHEORS, Patna, BR, India
[7] MSD, Zurich, Switzerland
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE562
引用
收藏
页数：2
相关论文
共 50 条
  • [31] PUBLIC HEALTH AND ECONOMIC IMPACT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN AN INFLUENZA PANDEMIC IN SINGAPORE AND HONG KONG
    Rubin, J.
    McGarry, L.
    Klugman, K.
    Strutton, D.
    Gilmore, K.
    Hwang, S.
    Rinaldi, F.
    Weinstein, M.
    VALUE IN HEALTH, 2010, 13 (03) : A9 - A9
  • [32] A cost-effectiveness analysis of vaccinating older adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) compared to no vaccination, the 13-valent pneumococcal conjugate vaccine (PCV13), or PCV13 followed by PPV23 in Colombia
    Prieto, E.
    Jiang, Y.
    Yang, X.
    Graham, J. B.
    Monsanto, H.
    Ruiz, J.
    Beltran, C.
    Rojas, M.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 73 : 13 - 13
  • [33] COST-EFFECTIVENESS ANALYSIS OF JOINT VACCINATION WITH 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) AND INFLUENZA VACCINE IN TAIWAN DURING SEASONAL INFLUENZA
    Wu, D. B. C.
    Chong, H. Y.
    Lee, K. K. C.
    VALUE IN HEALTH, 2014, 17 (03) : A273 - A273
  • [34] Evolution over time in the cost-effectiveness of pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant vaccination
    Chen, C.
    Beutels, P.
    Newall, A. T.
    VACCINE, 2018, 36 (16) : 2057 - 2060
  • [35] Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants"
    Gomez, Jorge A.
    Guevara, Javier Nieto
    Carlos, Josefina C.
    de Castro, Joanne A.
    Josue, Donald Ray
    Rodriguez, Edwin
    INFECTIOUS DISEASES AND THERAPY, 2022, 11 (04) : 1757 - 1761
  • [36] Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
    Jorge A. Gomez
    Javier Nieto Guevara
    Josefina C. Carlos
    Joanne A. de Castro
    Donald Ray Josue
    Edwin Rodriguez
    Infectious Diseases and Therapy, 2022, 11 : 1757 - 1761
  • [37] The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults
    Feldman, Charles
    Dlamini, Sipho K.
    Madhi, Shabir A.
    Meiring, Susan
    von Gottberg, Anne
    de Beer, Janetta C.
    de Necker, Margreet
    Stander, Marthinus P.
    PLOS ONE, 2020, 15 (01):
  • [38] A Response to: Letter to the Editor Regarding “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
    Johnna Perdrizet
    Emily K. Horn
    Winniefer Nua
    Judith Perez-Peralta
    Jennifer Nailes
    Jaime Santos
    Anna Ong-Lim
    Infectious Diseases and Therapy, 2022, 11 : 1301 - 1303
  • [39] A Response to: Letter to the Editor Regarding "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants"
    Perdrizet, Johnna
    Horn, Emily K.
    Nua, Winniefer
    Perez-Peralta, Judith
    Nailes, Jennifer
    Santos, Jaime
    Ong-Lim, Anna
    INFECTIOUS DISEASES AND THERAPY, 2022, 11 (03) : 1301 - 1303
  • [40] COST-EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT CONJUGATE (PCV13) AND 23-VALENT (PPV23) POLYSACCHARIDE PNEUMOCOCCAL VACCINES FOR ADULTS IN SWEDEN
    Dorange, A.
    Nyman, L.
    VALUE IN HEALTH, 2016, 19 (03) : A216 - A217
12345